This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Fixed Versus Flexible Gonadotropin-releasing Hormone (GnRH) Antagonist Initiation

This study has been completed.
Information provided by:
Aristotle University Of Thessaloniki Identifier:
First received: November 13, 2007
Last updated: October 30, 2009
Last verified: October 2009
This is a comparison of pregnancy achievement between two GnRH antagonist protocols which differ in the timing of GnRH antagonist initiation.

Condition Intervention Phase
Subfertility Drug: Cetrorelix (Cetrotide) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fixed Versus Flexible GnRH Antagonist Initiation

Resource links provided by NLM:

Further study details as provided by Aristotle University Of Thessaloniki:

Primary Outcome Measures:
  • Luteinizing hormone rise [ Time Frame: 3-14 days (duration of ovarian stimulation) ]

Enrollment: 146
Study Start Date: June 2005
Study Completion Date: March 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: fixed Drug: Cetrorelix (Cetrotide)
fixed antagonist administration on day 6 of ovarian stimulation
Other Name: Cetrorelix, Cetrotide, Serono
Experimental: flexible Drug: Cetrorelix (Cetrotide)
flexible antagonist administration according to specified criteria
Other Name: Cetrorelix, Cetrotide, Serono


Ages Eligible for Study:   18 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • < 39 years of age
  • BMI 18.5-29.9
  • <= 3 previous IVF cycles

Exclusion Criteria:

  • PCOS
  • Endometriosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01005784

Unit for Human Reproduction
Thessaloniki, Greece
Sponsors and Collaborators
Aristotle University Of Thessaloniki
Principal Investigator: Efstratios Kolibianakis Unit for Human Reproduction
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Prof. Basil Tarlatzis, Medical School, Aristotle University of Thessaloniki Identifier: NCT01005784     History of Changes
Other Study ID Numbers: UHR-3
Study First Received: November 13, 2007
Last Updated: October 30, 2009

Keywords provided by Aristotle University Of Thessaloniki:
GnRH antagonists

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on August 17, 2017